Screener
Johnson & Johnson JNJ Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $16.38B+7.8% | $15.43B+11.2% | $15.76B+10.0% | $15.56B+6.7% | $15.2B+4.9% | |
| MEDTECH | $8.93B+4.5% | $8.64B+7.7% | $8.8B+7.5% | $8.43B+6.8% | $8.54B+7.3% | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $1.19B+2.1% | $1.12B+4.7% | $1.18B+2.1% | $1.17B+5.0% | $1.16B+2.0% | |
| CAPLYTA | $361M+71.1% | $270M— | $249M— | $240M— | $211M— | |
| CARVYKTI | $657M+49.7% | $597M+61.8% | $555M+66.2% | $524M+83.2% | $439M+136% | |
| CONCERTA/Methylphenidate | $146M-11.0% | $136M-8.1% | $132M-17.0% | $140M-1.4% | $164M+0.6% | |
| CONTACT LENSES / OTHER | $1.03B+6.2% | $969M+5.4% | $1.01B+7.6% | $1.02B+5.2% | $965M+5.1% | |
| DARZALEX | $4.21B+18.9% | $3.96B+22.5% | $3.9B+26.6% | $3.67B+21.8% | $3.54B+23.0% | |
| EDURANT/rilpivirine | $350M-2.8% | $409M+14.2% | $383M+18.9% | $385M+16.7% | $360M+21.2% | |
| ERLEADA | $995M+9.6% | $949M+23.1% | $959M+22.3% | $936M+18.5% | $908M+23.4% | |
| GENERAL | $1.46B+5.2% | $1.39B+4.9% | $1.47B+8.2% | $1.38B+4.0% | $1.39B+3.3% | |
| HIPS | $441M+4.8% | $436M+6.6% | $439M+5.0% | $405M+6.3% | $421M+1.0% | |
| IMBRUVICA | $599M-18.5% | $660M-6.9% | $684M-6.4% | $695M-7.7% | $735M-4.5% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $1.02B+2.3% | $1.04B+15.0% | $986M-7.2% | $929M-11.4% | $992M-5.9% | |
| KNEES | $410M+5.4% | $420M+8.0% | $432M+8.5% | $377M+7.1% | $389M-1.3% | |
| OPSUMIT/OPSYNVI | $602M+3.4% | $606M+16.1% | —— | $578M-0.9% | $582M+6.2% | |
| OTHER IMMUNOLOGY | $104M+1,200% | $46M+4,500% | $40M— | $12M+1,100% | $8M+300% | |
| OTHER INFECTIOUS DISEASES | $41M-12.8% | $37M-9.8% | $40M-11.1% | $47M-16.1% | $47M-79.8% | |
| OTHER NEUROSCIENCE | $232M-14.1% | $262M-5.4% | $245M-3.9% | $256M-8.9% | $270M-8.2% | |
| Other Oncology | $226M-5.0% | $192M-10.3% | $100M+33.3% | $94M+9.3% | $238M+187% | |
| Other | $2.8B-1.8% | $2.9B+2.1% | $249M-11.4% | $264M-9.6% | $2.85B+833% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $372M-6.1% | $443M+9.9% | $383M-5.9% | $397M-11.6% | $396M-9.6% | |
| Remicade | $338M-25.7% | $422M-9.6% | $370M+3.1% | $476M+13.6% | $455M+15.8% | |
| RYBREVANT + LAZCLUZE | $289M+61.5% | $257M+82.3% | $216M+77.0% | $198M+122% | $179M+159% | |
| SIMPONI / SIMPONI ARIA | $618M-10.4% | $647M-1.8% | $632M+8.4% | $687M+33.1% | $690M+28.5% | |
| SPINE & OTHER | $740M+1.8% | $694M+3.4% | —— | $698M+0.3% | $727M-2.2% | |
| SPRAVATO | $584M+41.1% | $468M+46.3% | $503M+69.4% | $459M+61.6% | $414M+52.8% | |
| STELARA | $740M-55.2% | $656M-59.6% | $1.23B-47.6% | $1.57B-41.3% | $1.65B-42.7% | |
| SURGICAL | $426M+5.7% | $396M+9.7% | $411M+12.6% | $383M+15.0% | $403M+9.8% | |
| TALVEY | $174M+64.2% | $152M+76.7% | $149M+75.3% | $122M+62.7% | $106M+53.6% | |
| Tecvayli | $260M+56.6% | $202M+33.8% | $176M+20.5% | $177M+31.1% | $166M+23.0% | |
| TRAUMA | $827M+7.7% | $833M+7.9% | $813M+6.4% | $793M+4.2% | $768M+1.2% | |
| Tremfya | $2.05B+72.5% | $1.61B+68.2% | $1.59B+67.4% | $1.42B+41.4% | $1.19B+30.9% | |
| UPTRAVI | $494M+3.8% | $483M+7.1% | $491M+5.6% | $484M+5.7% | $476M+11.7% | |
| XARELTO | $664M+6.9% | $642M-7.0% | $687M+1.6% | $635M+7.3% | $621M+5.8% | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $3.74B+3.8% | $3.59B+8.5% | $3.5B+7.4% | $3.61B+4.0% | $3.61B+4.5% | |
| Europe | $5.73B+6.3% | $5.85B+14.4% | $5.6B+13.8% | $5.44B+10.7% | $5.39B+3.3% | |
| United States | $14.53B+7.3% | $13.33B+8.3% | $14.2B+7.5% | $13.71B+6.2% | $13.54B+7.8% | |
| Western Hemisphere, excluding U.S. | $1.31B+8.5% | $1.29B+10.8% | $1.27B+12.0% | $1.23B+4.9% | $1.21B-0.5% |
FAQ
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
